Recommendations for the Equitable and Widespread Implementation of Liquid Biopsy for Cancer Care.


Journal

JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370

Informations de publication

Date de publication:
Jan 2024
Historique:
medline: 3 1 2024
pubmed: 3 1 2024
entrez: 2 1 2024
Statut: ppublish

Résumé

Liquid biopsies-tests that detect circulating tumor cellular components in the bloodstream-have the potential to transform cancer by reducing health inequities in screening, diagnostics, and monitoring. Today, liquid biopsies are being used to guide treatment choices for patients and monitor for cancer recurrence, and promising work in multi-cancer early detection is ongoing. However, without awareness of the barriers to adoption of this new technology and a willingness to build mitigation efforts into the implementation of widespread liquid biopsy testing, the communities that could most benefit may be the last to access and use them. In this work, we review the challenges likely to affect the accessibility of liquid biopsies in both the general population and underserved populations, and recommend specific actions to facilitate equitable access for all patients.

Identifiants

pubmed: 38166232
doi: 10.1200/PO.23.00382
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300382

Auteurs

Emma B Alme (EB)

Guardant Health, Palo Alto, CA.

Robert Dumanois (R)

Thermo Fisher Scientific, Waltham, MA.

Alessia Essig (A)

AstraZeneca, Cambridge, United Kingdom.

Estevan Kiernan (E)

Illumina, San Diego, CA.

Caitlin B Kubler (CB)

Prevent Cancer Foundation, Alexandria, VA.

Nikki Martin (N)

LUNGevity Foundation, Chicago, IL.

Lauren C Leiman (LC)

BLOODPAC, Chicago, IL.

Classifications MeSH